R1 Therapeutics is debuting with an oversubscribed $77.5 million series A financing aimed at advancing its first-in-class therapy for chronic kidney disease (CKD) patients on dialysis with high ...
March 17 (Reuters) - R1 Therapeutics said on Tuesday it had launched operations with a $77.5 million Series A funding round and an exclusive license ‌to develop and commercialize a drug for high ...
Series A co-led by Abingworth, DaVita Venture Group, and F-Prime with participation from Curie.Bio, SymBiosis, and U.S. Renal Care Partnership with Alebund Pharmaceuticals to gain exclusive global ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results